Professor Martin Gotthardt of Radboud University Medical Centre in Nijmagen, The Netherlands, gave the following presentation at the 2024 Congenital Hyperinsulinism International Family Conference in Liverpool, UK.
The LightCure Consortium is developing a targeted photodynamic therapy, that one day could be a promising treatment for congenital hyperinsulinism (HI). This project is made possible by a grant of just over €8.2M from the European Union research arm Horizon Europe and encompasses CHI’s work to strengthen patient engagement and raise worldwide awareness of HI and its myriad challenges.